Somewhere in a poison control facility, a telephone rings, and the individual on the other end has been administering their weight-loss medication every single day. They were instructed to take it weekly. Even more concerning, they began at the full dosage instead of gradually increasing it. The call is documented, categorized in close to real-time by a specialist knowledgeable in clinical toxicology, and entered into a national database. Multiply that scenario by thousands, year after year, and you uncover one of the more peculiar public health indicators of the decade: a medication famous for reducing waistlines was inundating the nation\u2019s poison hotlines.<\/p>\n
Throughout most of the 2010s, those hotlines received between 1,000 and 1,500 calls annually regarding this entire category of drugs. By 2023, the total surpassed 8,000. Something had shifted, and it had a specific date.<\/p>\n
The category in question is the glucagon-like peptide-1 receptor agonists, abbreviated GLP-1RAs, including semaglutide, the active component marketed as Ozempic and Wegovy. These medications replicate a gut hormone, slowing stomach emptying, dulling hunger, and steering the body toward feelings of fullness. They were initially developed as treatments for diabetes. However, on June 4, 2021, the US Food and Drug Administration authorized once-weekly semaglutide for chronic weight management, transforming a medical product into a cultural phenomenon.<\/p>\n
Jordan Miller sought to determine whether the timing was a mere coincidence or a causal relationship. As an undergraduate at the University of Texas at San Antonio, she searched for a research question and stumbled upon one concealed within the noise of poison center information.<\/p>\n
\u201cOne of them was this quite peculiar category of semaglutide,\u201d remembers David Han, the Romo Endowed Professor in the university\u2019s Department of Statistics and Data Science, who oversaw the project. \u201cWe suspected that the call volume was surging due to the misuse and mishandling of this drug and that it could be linked to the FDA\u2019s approval for weight management.\u201d That was the hypothesis. The task was to validate it.<\/p>\n
A Different Crowd, A Different Story<\/p>\n
Collaborating with poison center associates from the Long School of Medicine, the team extracted twelve years of data from the National Poison Data System, documenting every human GLP-1RA exposure recorded between 2012 and 2023. They marked a line at July 1, 2021, immediately following the FDA\u2019s ruling, and examined what appeared distinct on either side of it. The finding was: nearly everything.<\/p>\n
Prior to the cutoff, the records documented 3,113 exposures. Following it, 6,920, about 2.2 times as many. Semaglutide, which constituted roughly a quarter of cases previously, now dominated at 64.2 percent. Additionally, the demographics of those making the calls had changed. The average patient aged younger (the mean age of new cases fell by around ten years, to 47.5) and became significantly more likely to be female, with the proportion of women increasing from 68.9 to 78.2 percent of cases. This was no longer a story about diabetes.<\/p>\n
\u201cIn that figure tracking the increase by specific drug, I wasn\u2019t anticipating semaglutide to be so strikingly dominant,\u201d Miller stated. \u201cI expected it to lead, but the extent was shocking. On the flip side, it aligns with all the media coverage.\u201d<\/p>\n
Han presents the distinction straightforwardly. \u201cWhen GLP-1[RA] drugs are marketed to diabetic patients, that narrative is entirely different from when the drug is utilized for weight management,\u201d he remarked. A long-established diabetic population is one thing. A considerable influx of first-time users, many self-guided and influenced by constant media attention, is quite another.<\/p>\n
The Errors Hiding in the Numbers<\/p>\n
Here lies the aspect that should both comfort and disturb. The vast majority of these exposures were not overdoses in any significant sense, nor were they intentional. They were unintentional therapeutic missteps, the ordinary blunders of individuals misunderstanding the dosage, and most resulted in nothing beyond nausea, vomiting, or an upset stomach. To conduct a proper statistical analysis, the researchers modeled the quarterly call counts using segmented Poisson regression, a method designed to discern whether a known event alters a trend or simply follows existing growth. It changed. Semaglutide exposures surged by an additional 9.9 percent per quarter after the approval, while the rest of the drug class hardly shifted, a divergence that points directly to the new weight-loss indication rather than an incremental rise. Two errors consistently surfaced: individuals injecting daily when the medication is formulated for weekly use, and individuals commencing at the full dose instead of gradually titrating. By sheer numbers, \u201cwrong dose\u201d led the count at over 5,000 cases.<\/p>\n","protected":false},"excerpt":{"rendered":"
Somewhere in a poison control facility, a telephone rings, and the individual on the other end has been administering their weight-loss medication every single day. They were instructed to take it weekly. Even more concerning, they began at the full dosage instead of gradually increasing it. The call is documented, categorized in close to real-time […]<\/p>\n","protected":false},"author":1,"featured_media":373400,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[179],"class_list":["post-373399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-source-scienceblog-com"],"_links":{"self":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts\/373399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=373399"}],"version-history":[{"count":0,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts\/373399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/media\/373400"}],"wp:attachment":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=373399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=373399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=373399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}